Supervivencia de pacientes con cáncer de pulmón de célula no pequeña en cuatro instituciones de Colombia

OBJECTIVE: Describing results of treatment in patients suffering advanced no small cell according to routine clinical practice. The 70 % of patients suffering debut with advanced disease are determining less than 13 % overall survival in 5 years. METHODS: 176 patients treated in Bogotá. RESULTS: The mean age was 64 years; 64 % were male 51 % had ≤1 ECOG. The 90 % had metastasis, mainly in the lung and in central nervous system. 76 % received combined therapy as the first line of intervention; 126 subjects were treated with a platinum compounds (cisplatin 38/21.6 % carboplatin 88/50 %) plus some third generation agent or etoposide. Thirty-four received monotherapy and eight erlotinib; 3.7 ± 1.7 cycles per patient were supplied on average, overall response rate was 29 %, clinical benefit 39 % and the median time to progression was 3.4 months. Only the third part of the population received a second line intervention; in this group overall response was 15.8 %, clinical benefit 33.8 % and free time progression was 3.1 months. When follow-up finished, 69.3 % had died, median the overall survival was 9.2 months 26 % of the subjects lived for up to one year. Some variables such gender, functional state, history of smoking, administering second line agent and a diagnosis of adenocarcinoma influenced in superlife. CONCLUSIONS: Clinical behaviour and outcomes treatment of patients included in this study were similar to those previously reported in the medical literature.